Vita Life Sciences Limited · ASX:VLS
Vita Life Sciences — Shareholder Meeting (May 2024)
40 slides from Vita Life Sciences's shareholder meeting presentation, May 22, 2024
Slide 1: 2024 Annual General Meeting (AGM) - Address & Presentation
22 May 2024 Market Announcements Australian Securities Exchange Ltd 20 Bridge Street Sydney, NSW 2000 Dear Sir/ Madam, 2024 ANNUAL GENERAL MEETING (AGM)-ADDRESS & PRESENTATION The Vita Life Sciences Ltd addresses to the 2024 AGM by the Chairman and the Managing Director with related presentation is
Slide 2: Chairman's Script - 22 May 2024
Vita Life Sciences Limited – 2024 Annual General Meeting Chairman’s Script - 22 May 2024 Welcome Good afternoon ladies and gentlemen. I’m Henry Townsing, the Chairman of Vita Life Sciences Limited and the Chairman for the Annual General Meeting today. Welcome to the VLS 2024 Annual General Meeting.
Slide 3: Agenda 1 Managing Director's Presentation
As this meeting is being conducted as a hybrid meeting, I would like to welcome those shareholders that are joining us online and ask that you please submit any questions or comments via the Q&A function which can be found at the bottom of your screen. When you submit a question or comment, please s
Slide 4: Poll and voting instructions
For the purposes of the poll, I appoint the representative of Automic, the Company’s share registry, who has examined and prepared summaries of the proxy forms received, to act as Returning Officer and to conduct the poll. Shareholders in attendance online who have already submitted their votes by p
Slide 5: 2023 Financial Reports and Remuneration Report
auditors are now laid before the meeting. There will be no vote on this item as it is a discussion item only. The Company’s auditor for the 2023 financial year, Mr Stephen Fisher of Nexia Sydney Audit Pty Ltd is present to take questions relevant to the conduct of the audit and the preparation and c
Slide 6: Resolution 1: Adoption of the Remuneration Report
If you have any questions or wish to discuss this resolution, please submit your questions via the Q&A. [PAUSE AND TAKE QUESTIONS] Members of the Company’s key management personnel who were named in the FY2023 remuneration report and their closely related parties are reminded that they may not vote
Slide 7: Resolution 3: Re-election of Director - Mr Peter Osborne
If there are no further questions I shall move to the next resolution. Resolution 3: Re-election of Director- Mr Peter Osborne To consider and, if thought fit, to pass, with or without amendment, Resolution 3, as an ordinary resolution. “That Peter Osborne, a director retiring in accordance with rul
Slide 8: Resolution 4: Share buy-back
announcement to the ASX, the on-market buy-back of up to 15% of the fully paid ordinary shares in the Company expiring on whichever is the earlier of the anniversary of the passage of this resolution or the 2025 Annual General Meeting and otherwise on the terms and conditions set out in the Explanat
Slide 9: Resolution 6: Long Term Incentive Plan
The number of valid proxy votes that have been received on this motion are shown on the screen. If you have any questions or wish to discuss this resolution, please submit your questions via the Q&A. [PAUSE AND TAKE QUESTIONS] Shareholders may now vote on Resolution 5. I again remind shareholders no
Slide 10: Resolution 7: Loan to Director to Purchase Shares
Resolution 7: Long Term Incentive Plan: Grant of A Limited Recourse Loan to a Director to Purchase Ordinary Shares I put forward the following motion under Resolution : To consider and, if thought fit, to pass, with or without amendment, Resolution 7, as an ordinary resolution. “That pursuant to ASX
Slide 11: Poll closed and other business
Can all shareholders voting online please ensure that you have submitted your votes – I will allow another minute before declaring the poll is closed. If you have any questions in relation to the submission of online votes, please send them through the Q&A function now. I will now pause for about on
Slide 12: Address by the Managing Director
Vita Life Sciences Limited – 2024 Annual General Meeting Address by the Managing Director – 22nd May 2024 Opening remarks Thank you, Henry. Good afternoon and a warm welcome to all shareholders, VLS directors and the Executive Team. Thank you for joining the Company’s Annual General Meeting. It is m
Slide 13: Regional growth and strategic outlook
consumers is extremely encouraging and will underpin the Group’s growth expectations moving forward. Our strategic partnership in China continued to generate revenue growth through cross-border e- commerce (CBEC) activities and unsophisticated Daigou trading. China’s performance across traditional e
Slide 14: Key strategic priorities and outlook
• Continued investments across major e-commerce platforms to leverage Chinese consumer demand. • Expanding the VitaHealth brand into modern trade pharmacies across Malaysia and Singapore. • Launching the Herbs of Gold range into Con Cung through an exclusive strategic partnership. Over the next 12 m
Slide 15: Annual General Meeting May
Annual General Meeting 22 May 2024
Slide 16: Agenda
Agenda 1. CHAIRMAN’S WELCOME ADDRESS 2. MANAGING DIRECTOR’S REVIEW 3. ORDINARY RESOLUTIONS 4. QUESTIONS & ANSWERS
Slide 17: Henry Townsing
Henry Townsing Chairman Mr Townsing brings over 30 years’ experience in corporate finance and private equity. He was a Director of the Company, from 1985 to 1992, 2004 to 2009 and was reappointed a Director on 22nd December 2011. Mr Townsing was appointed as the Chairman of the Company effective 28t
Slide 18: Agenda
Agenda 1. CHAIRMAN’S WELCOME ADDRESS 2. MANAGING DIRECTOR’S REVIEW 3. ORDINARY RESOLUTIONS 4. QUESTIONS & ANSWERS
Slide 19: Andrew O'Keefe
Andrew O’Keefe Managing Director Mr O’Keefe was appointed Managing Director on 1st January 2017. Prior to his Managing Director appointment, Mr O’Keefe was the Chief Executive Officer of Herbs of Gold Australia. He has over 20 years’ experience within the Australian pharmaceutical and healthcare ind
Slide 20: A Snapshot of the Vita Life Sciences Group
A Snapshot of the Vita Life Sciences Group One of Australia’s & South East AUD74M+ in annual net High quality standards in sourcing & Over 350+ premium healthcare & Over 400 employees Asia’s leading natural healthcare revenue; strong balance sheet manufacturing pharmaceutical products across Austral
Slide 21: Financial Performance
Financial Performance BALANCE SHEET RECORD SALES PRE-TAX PROFIT EQUITY DIVIDEND PAYMENT $74.2M, UP 11% $12.5M, UP 16% 9.00 CENTS/SHARE, $43.3M,NET CASH $24.6M UP 50% (WITHOUT ANY BORROWINGS) ANNUAL GENERAL MEETING 2024
Slide 22: Global Performance and Footprint
Global Performance and footprint Other Asia 2% Australia 59% $1.6M $43.5M Singapore 8% $6.3M Asia 41% 2023 revenue by geography Malaysia 31% $22.8M ANNUAL GENERAL MEETING 2024
Slide 23: Our awards
Our awards Australia Malaysia Singapore VOICE OF THE CUSTOMER BEST BRAND SINGAPORE CONSUMERS’ CHOICE 2023/2024 ADVANTAGE PHARMACY PROGRAM 2023 STAR OUTSTANDING BUSINESS AWARDS 2023 SINGAPORE MARKETING EXCELLENCE AWARD 2023 BEST COMPLEMENTARY MEDICINE BRAND MOST WANTED SUPPLEMENT FOR SKIN BRIGHTENING
Slide 24: Vietnam market launch
Vietnam market launch ANNUAL GENERAL MEETING 2024
Slide 25: Marketing Reach
Marketing Reach ANNUAL GENERAL MEETING 2024
Slide 26: Strategic priorities
Strategic priorities Our pillars EDUCATION STRATEGIC OPERATIONAL BRANDBUILDING & INNOVATION PARTNERSHIPS LEVERAGE Key initiatives to support our pillars CONTINUATION OF LAUNCH OF OUR NEW CONSUMER LED INVESTEMENT BACK NEWBUSINESS EXISTING CHANNEL TRAINING PORTAL FOR PRODUCT INTO FUTURE GROWTH NEWPROD
Slide 27: Outlook
-Driving brand performance across our respective markets will be paramount to the ongoing business trajectory -Our product proposition and channel strategies across our respective markets remains robust Outlook - The business continues to track well against expectations in FY24 -Management remains c
Slide 28: Annual General Meeting 2024
ANNUAL GENERAL MEETING 2024
Slide 29: Agenda
Agenda 1. CHAIRMAN’S WELCOME ADDRESS 2. MANAGING DIRECTOR’S REVIEW 3. ORDINARY RESOLUTIONS 4. QUESTIONS & ANSWERS ANNUAL GENERAL MEETING 2024
Slide 30: Resolutions
Resolutions 1. Remuneration Report 2. Re-election of Director – Jack Teoh 3. Re-election of Director- Peter Osborne 4. Share buy back 5. Approval to replace Constitution (Special) 6. Long Term Incentive Plan 7. Long Term Incentive Plan: Grant of a limited recourse loan to a Director to purchase ordi
Slide 31: Proxy-Resolution 1
Proxy-Resolution 1 PROXY’S RESOLUTIONS IN FAVOUR AGAINST EXCLUDED DISCRETION 1 Adoption of the Remuneration Report 4,649,562 73,522 22,739,245 9,673,293 ANNUAL GENERAL MEETING 2024
Slide 32: Proxy-Resolution 2
Proxy-Resolution 2 PROXY’S RESOLUTIONS IN FAVOUR AGAINST EXCLUDED DISCRETION Re-election of Director 2 14,398,666 26,064 22,739,245 0 (Jack Teoh) ANNUAL GENERAL MEETING 2024
Slide 33: Proxy-Resolution 3
Proxy-Resolution 3 PROXY’S RESOLUTIONS IN FAVOUR AGAINST EXCLUDED DISCRETION Re-election of Director 3 14,402,815 21,915 22,739,245 0 (Peter Osborne) ANNUAL GENERAL MEETING 2024
Slide 34: Proxy-Resolution 4
Proxy-Resolution 4 PROXY’S RESOLUTIONS IN FAVOUR AGAINST EXCLUDED DISCRETION 4 Share buy-back 14,386,559 34,395 22,739,728 0 ANNUAL GENERAL MEETING 2024
Slide 35: Proxy-Resolution 5 (Special)
Proxy-Resolution 5 (Special) PROXY’S RESOLUTIONS IN FAVOUR AGAINST EXCLUDED DISCRETION 5 Approval to replace Constitution 14,378,008 34,901 22,739,728 0 ANNUAL GENERAL MEETING 2024
Slide 36: Proxy-Resolution 6
Proxy-Resolution 6 PROXY’S RESOLUTIONS IN FAVOUR AGAINST EXCLUDED DISCRETION 6 Long Term Incentive Plan 4,652,766 71,335 22,739,245 9,673,293 ANNUAL GENERAL MEETING 2024
Slide 37: Proxy-Resolution 7
Proxy-Resolution 7 PROXY’S RESOLUTIONS IN FAVOUR AGAINST EXCLUDED DISCRETION Long Term Incentive Plan: Grant of a 7 limited recourse loan to a Director to 4,643,199 80,152 22,739,728 9,673,293 purchase ordinary shares ANNUAL GENERAL MEETING 2024
Slide 38: Proxy
Proxy PROXY’S RESOLUTIONS IN FAVOUR AGAINST EXCLUDED DISCRETION 1 Adoption of the Remuneration Report 4,649,562 73,522 22,739,245 9,673,293 Re-election of Director 2 14,398,666 26,064 22,739,245 0 (Jack Teoh) Re-election of Director 3 14,402,815 21,915 22,739,245 0 (Peter Osborne) 4 Share buy-back 1
Slide 39: Agenda
Agenda 1. CHAIRMAN’S WELCOME ADDRESS 2. MANAGING DIRECTOR’S REVIEW 3. ORDINARY RESOLUTIONS 4. QUESTIONS & ANSWERS ANNUAL GENERAL MEETING 2024
Slide 40: Disclaimer
Disclaimer This document has been prepared by Vita Life Sciences Limited (Vita Life Sciences) and comprises written material/slides for a presentation concerning Vita Life Sciences. The presentation is for information purposes only and does not constitute or form part of any offer or invitation to a